Avenanthramide

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Retrieved on: 
Monday, February 26, 2024
TSX, Toronto Stock Exchange, Exercise, Transaction, Aeterna, Avenanthramide, Text, Pharmacy, Proxy, Neutrogena, Aveeno, Research, Management

These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.

Key Points: 
  • These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.
  • The issuance of Aeterna Zentaris Shares, Transaction Warrants and Replacement Options by Aeterna Zentaris under the Transaction is subject to the approval of a simple majority of the votes cast by Aeterna shareholders at a special meeting of Aeterna Zentaris shareholders.
  • ISS recommended that Aeterna Zentaris shareholders vote FOR all of these resolutions as part of the Transaction.
  • Aeterna Zentaris and Ceapro securityholders must vote their proxy before 11:00 a.m. (Eastern time) on March 8, 2024.

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company

Retrieved on: 
Monday, February 26, 2024
TSX, Toronto Stock Exchange, Exercise, Transaction, Aeterna, Avenanthramide, Text, Pharmacy, Proxy, Neutrogena, Aveeno, Research, Management

These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.

Key Points: 
  • These revenue streams will be used to support the development of high potential-return products and represent a more diversified value proposition for investors.
  • The issuance of Aeterna Zentaris Shares, Transaction Warrants and Replacement Options by Aeterna Zentaris under the Transaction is subject to the approval of a simple majority of the votes cast by Aeterna shareholders at a special meeting of Aeterna Zentaris shareholders.
  • ISS recommended that Aeterna Zentaris shareholders vote FOR all of these resolutions as part of the Transaction.
  • Aeterna Zentaris and Ceapro securityholders must vote their proxy before 11:00 a.m. (Eastern time) on March 8, 2024.

Ceapro Inc. Announces the Mailing of Meeting Materials in Connection With the Special Meeting of Securityholders to Approve Merger With Aeterna Zentaris

Retrieved on: 
Thursday, February 15, 2024
Court, Issuer, Shareholder, Arrangement, Post office box, Meeting, TSX, Toronto Stock Exchange, News, Aeterna, Avenanthramide, Proxy, Pharmacy, Knowledge, Neutrogena, Aveeno, Internet, Security (finance)

The Board believes this is a compelling opportunity for Ceapro and its investors for a number of reasons, including:

Key Points: 
  • The Board believes this is a compelling opportunity for Ceapro and its investors for a number of reasons, including:
    Recurring revenue to support business expansion.
  • The pipeline of products being developed should generate an increased and consistent news flow, a key supporting factor in investor interest.
  • Only Securityholders of record as of the close of business on January 12, 2024 are eligible to vote at the Meeting.
  • Registered Securityholders and duly appointed proxyholders may vote on matters presented at the Meeting by:
    Virtually – completing a ballot online during the Meeting.

Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 29, 2023
Urine, Symrise, Regeneration, Avenanthramide, Research, Hand, McMaster University, Blood, MBA, Coenzyme Q10, The Angiogenesis Foundation, Animal, NATEX, Appetite, CZO, Completeness, Growth, Investment, Safety, YTD, YBG, Pharmaceutical industry

EDMONTON, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • Further, over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange.
  • Such formulations are to be resolubilized locally by Symrise and used for hair care and facial masks.
  • Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2023
    Total sales of $2,619,000 for the third quarter of 2023 and $7,983,000 for the first nine months of 2023 compared to $3,845,000 and $15,517,000 for the comparative periods in 2022.
  • Cash flows used in operations of $2,017,000 for the first nine months in 2023 vs cash generated from operations of $5,644,000 in 2022.

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Retrieved on: 
Monday, November 27, 2023
Montreal Heart Institute, Cytokine, C-reactive protein, Avenanthramide, Research, Blood, MBA, Lipoxygenase, Inflammation, Pharmacokinetics, Observation, CZO, SAD, Biomarker, Nitric oxide, Patient, Safety, Cardiovascular disease, Research institute, Polyphenol, Chemokine

EDMONTON, Alberta, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

Key Points: 
  • This Phase 1-2a study (“AvenActive”) is a double-blind, placebo-controlled, randomized, adaptive, first-in-human study designed to assess safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of avenanthramide.
  • Following the Phase 1 portion, pending successful results, the AvenActive protocol also includes a Phase 2a portion for patients presenting evidence of mild to moderate inflammation.
  • Pending successful results in the Phase 1 and potential Phase 2a study, we believe we will be well-positioned for out-licensing opportunities for later stage development and commercialization.
  • With significant market potential and patient benefit, we believe avenanthramides is poised to be the biggest product for Ceapro,” concluded Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.

Kao Announces the Launch of re/cover A First of Its Kind Eczema Relief System

Retrieved on: 
Wednesday, October 18, 2023
Adhesive, Skin, Aesculus, Dermatitis, Allantoin, Paraben, Kao, Serum, Avenanthramide, Pharmaceutical industry, Cosmetics

With a steadfast commitment to consumer well-being, Kao has developed a revolutionary system featuring patented technology that provides eczema relief while addressing the pain points often associated with existing treatments on the market.

Key Points: 
  • With a steadfast commitment to consumer well-being, Kao has developed a revolutionary system featuring patented technology that provides eczema relief while addressing the pain points often associated with existing treatments on the market.
  • re/cover represents a paradigm shift in the field of eczema management, offering a steroid-free, safe and highly effective solution that is accessible to consumers.
  • The system features a Calming Eczema Serum designed to relieve the itch paired with an invisible protective Moisture Patch to help recover healthy-looking skin.
  • "The launch of re/cover is a milestone moment for Kao," says Karen Frank, President, Consumer Care Business, Americas and EMEA.

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Thursday, May 25, 2023
GMP, Avenanthramide, Senior, Administration, Safety, Symrise, TSX Venture Exchange, Clinical trial, EPCM, G&A, MBA, Coenzyme Q10, Regulation and licensure in engineering, Trial of the century, YBG, Special Operations Executive, Regeneration, Ethics, Mask, The Angiogenesis Foundation, McMaster University, Organic acid, Pharmacokinetics, Investment, ALG, Mouse, Hand, Montreal Heart Institute, CZO, Skin, Technical, Wound healing, Pharmaceutical industry, Tolerability

EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • “Our team significantly advanced toward several key milestones related to new product development as well as strategic corporate initiatives.
  • Up to 96 subjects may be included in the study and dosages will escalate from 30 mg to 960 mg according to response.
  • Announced positive results from animal studies conducted by Angiogenesis Foundation on a wound healing model.
  • Financial Highlights for the First Quarter Ended March 31, 2023
    Total sales of $3,500,000 for the first quarter of 2023 compared to $6,172,000 for the comparative period in 2022.

Ceapro Inc. Reports 2022 Third Quarter and Nine-Month Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 9, 2022
Avenanthramide, Income, GLOBE, McMaster University, SA, YTD, Firestone Institute for Respiratory Health, Division, AVA, Pathology, Alginic acid, Pharmacokinetics, CTA, Safety, Department, Coenzyme Q10, Technology, Particle size, Health Canada, Jefferson Healthcare Hospital, The Company, CZO, YBG, Saint Joseph, Molecular medicine, Agriculture and Agri-Food Canada, Litre, Polymer, Fluid mechanics, Mitacs, Company, D, Saint Joseph's, Journal, Research, MBA, University, GMP, Letter, CEO, Organic acid, Oil, Management, Pharmaceutical industry, Beer, Fine chemical, Tolerability, Agriculture

EDMONTON, Alberta, Nov. 09, 2022 (GLOBE NEWSWIRE) --  Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2022.

Key Points: 
  • A response from Health Canada for clearance to proceed with this study is expected to be received within 90 days.
  • The second GMP clinical batches will also be manufactured, packaged and labeled in 2023 by Corealis Inc. GMP Manufacturing Services.
  • Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2022
    Total sales of $3,845,000 for the third quarter of 2022 and $15,517,000 for the first nine months of 2022 compared to $4,523,000 and $13,633,000 for the comparative periods in 2021.
  • Cash flows generated from operations of $5,644,000 for the first nine months in 2022 vs $2,837,000 in 2021.

P&G Ventures Reintroduces Bodewell, a Line of Gentle and Powerful Products, Specially Formulated for Eczema and Psoriasis

Retrieved on: 
Thursday, March 3, 2022
Other Consumer, Women, Other Retail, Men, Specialty, Other Health, Consumer, Health, Cosmetics, Retail, Cream, Avenanthramide, Steroid, Ambi, Psoriasis, News, Salicylic acid, Instagram, Invention, Solution, Dermatitis, Multimedia, Skin care, Nature, Skin, Paraben, P&G, Cosmetics, Phosphorus, Facebook

P&G Ventures has reintroduced Bodewell, a line of uniquely designed skin care products for people with eczema and psoriasis.

Key Points: 
  • P&G Ventures has reintroduced Bodewell, a line of uniquely designed skin care products for people with eczema and psoriasis.
  • View the full release here: https://www.businesswire.com/news/home/20220303005386/en/
    Bodewells products tackle tough skin issues like eczema and psoriasis with proven active ingredients and soothing botanicals.
  • (Photo: Business Wire)
    Bodewells new eczema and psoriasis lines feature gentle products with powerful results.
  • Bodewell eczema and psoriasis products help relieve symptoms such as itching and irritation.

Ceapro Inc. Announces Issuance of U.S. and European Patent for Flagship Product, Avenanthramides

Retrieved on: 
Tuesday, October 29, 2019
Food and drink, Foods, Articles, Cereals, Food science, Nutraceutical, Nutrition, Pharmacy, Alkaloid, Avenanthramide, Oat, Phenolic content in wine

10,334,869 entitled, Method For Increasing Concentration of Avenanthramides in Oats, related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada.

Key Points: 
  • 10,334,869 entitled, Method For Increasing Concentration of Avenanthramides in Oats, related to the production of its value-driver product, avenanthramides, utilizing a malting technology in-licensed from Agriculture and Agri-Food Canada.
  • Ceapro's flagship product, avenanthramides, is a group of phenolic alkaloids compounds uniquely found in oats and produced using a proprietary patented process.
  • Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals.
  • For more information on Ceapro, please visit www.ceapro.com and connect with the Company on Twitter , Facebook and LinkedIn .